Recent news highlights Viking Therapeutics' active clinical development in weight loss drugs beyond GLP-1, analyst optimism about its pipeline, and stock price volatility relative to the broader market. The company operates in a competitive environment with major pharmaceutical players advancing GLP-1 therapies.

• Viking Therapeutics has started testing a weight loss drug that goes beyond GLP-1, positioning it in a competitive obesity treatment market [N7].
• Wall Street analysts have shown optimism about Viking Therapeutics, reflecting interest in its drug development pipeline [N2].
• The company’s stock has experienced volatility, falling more steeply than the broader market at times, but also ascending during market declines [N3][N8].
• Viking Therapeutics operates in a competitive landscape with major players like Eli Lilly and Novo Nordisk advancing GLP-1 therapies, influencing market dynamics [N1][N4][N7].

Viking Therapeutics has a diversified pipeline with multiple drug candidates progressing through clinical trials, including a Phase 3 program for VK2735. The company’s exclusive licenses from Ligand Pharmaceuticals provide access to proprietary compounds. Recent positive clinical trial results and initiation of advanced studies indicate active development. Market interest and analyst optimism reflect potential value in its pipeline. The company is exploring weight loss drugs beyond GLP-1, which could differentiate it in a competitive market. Strong liquidity ratios as of mid-2026 provide runway for ongoing development activities.

Viking Therapeutics has not generated revenue and continues to incur significant losses, with a net loss of $128 million reported for Q2 2026. The company is involved in litigation with Ligand Pharmaceuticals over license termination, which could result in loss of rights to key drug candidates VK2809 and VK0214, materially impacting its business. Clinical development is inherently risky, with no guarantee of regulatory approval or commercial success. The company depends on third parties for clinical trials and manufacturing, adding execution risk. Competition from large pharmaceutical companies in the metabolic and weight loss drug markets is intense. Additional capital may be required, which could dilute shareholders or impose operational constraints.

Viking Therapeutics' moat is primarily based on its licensed intellectual property from Ligand Pharmaceuticals, which grants exclusive worldwide rights to key drug candidates. The company’s focus on metabolic and endocrine disorders, including novel approaches to weight loss drugs beyond GLP-1, positions it in a specialized niche. However, the company faces significant risks related to the potential loss of licensed rights due to ongoing litigation, the early stage of its drug candidates, and competition from established pharmaceutical companies with larger resources and approved products. Its moat is thus contingent on successful clinical development, regulatory approvals, and resolution of licensing disputes.

• Clinical Development Risk: The company’s drug candidates are in early to mid-stage clinical trials, with no pivotal Phase 3 trials completed except recently commenced studies for VK2735. Clinical trials may produce negative or inconclusive results, delaying or preventing regulatory approval.
• Licensing and Intellectual Property Risk: Viking Therapeutics depends on licensed technology from Ligand Pharmaceuticals. Ligand’s purported termination of the license for the TR-Beta Program has led to litigation. Loss of these licenses would harm the company’s ability to develop and commercialize key drug candidates.
• Financial Risk: The company has incurred significant losses and expects to continue incurring losses. It may require additional capital to fund operations, which may not be available on acceptable terms and could dilute existing shareholders.
• Competitive Risk: The company operates in a competitive market with large pharmaceutical companies developing similar therapies, including GLP-1 drugs. Competitors may obtain regulatory approval faster or market products more effectively.
• Operational Risk: Viking Therapeutics relies on third parties for clinical trials and manufacturing. Failure of these partners to meet obligations or regulatory requirements could adversely affect development timelines and outcomes.

• Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drug candidates for metabolic and endocrine disorders [S1].
• The company has not generated any revenue to date and does not expect revenue until regulatory approval and commercialization of drug candidates or collaborative agreements occur [S1].
• Key drug candidates include VK2735 (subcutaneous and oral formulations), VK2809, VK0214, VK5211, VK0612, VK3019, and preclinical programs DGAT-1 and EPOR [S1].
• VK2735 subcutaneous is in Phase 3 development; VK2809, VK5211, and VK0612 are in Phase 2; VK2735 oral recently completed Phase 2; VK0214 completed Phase 1b; VK3019 is in Phase 1 SAD trial; DGAT-1 and EPOR are in preclinical development [S1].
• The company incurred $344.955 million in research and development expenses in 2025, a significant increase from $101.644 million in 2024, primarily due to clinical studies and manufacturing costs [S1].
• General and administrative expenses were $48.387 million in 2025, slightly down from $49.277 million in 2024 [S1].
• As of June 30, 2026, Viking Therapeutics had cash and cash equivalents of $125.75 million, current assets of $517.564 million, current liabilities of $109.656 million, a current ratio of 4.72, and a cash ratio of 3.02 [S2].
• The company reported a net loss of $128.022 million and basic and diluted EPS of -$1.10 for the quarter ended June 30, 2026 [S2].
• Viking Therapeutics is substantially dependent on licensed technology from Ligand Pharmaceuticals under a Master License Agreement, which grants exclusive worldwide rights to key compounds including VK2809 and VK0214 [S1].
• Ligand purported to terminate the license for the TR-Beta Program (including VK2809 and VK0214) in April 2026, leading to litigation between the parties; Viking disputes the termination and seeks to retain rights [S2].
• The company faces risks typical of clinical-stage biopharmaceutical firms, including uncertainty of regulatory approval, clinical trial outcomes, and the need for additional capital [S1,S2].
• Viking Therapeutics has not yet completed pivotal clinical trials required for regulatory approval; Phase 3 studies for VK2735 have recently commenced [S1].
• The company relies on third parties for clinical trials and manufacturing, which introduces execution risks [S2].
• Recent news highlights Viking Therapeutics as an under-the-radar contender in the GLP-1 and weight loss drug market, with recent initiation of testing a weight loss drug beyond GLP-1 [N7].
• Wall Street analysts have shown optimism about Viking Therapeutics, reflecting interest in its drug development pipeline [N2].
• The company’s stock has experienced volatility, with periods of decline and ascent relative to broader market movements [N3,N8].
• Viking Therapeutics is developing drugs in a competitive landscape including major players like Eli Lilly and Novo Nordisk, with ongoing developments in GLP-1 therapies influencing market dynamics [N1,N4,N7].